vimarsana.com

Latest Breaking News On - Destiny crc01 - Page 1 : vimarsana.com

DESTINY-CRC02: Trastuzumab Deruxtecan in HER2+ Metastatic Colorectal Cancer

An overview of the DESTINY-CRC02 study, which looked at trastuzumab deruxtecan in patients with HER2+ metastatic colorectal cancer.

Tanioss bekaii saabColorectal cancerMetastatic colorectal cancerDestiny crc01Destiny crc02Trastuzumab deruxtecanKras mutations

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd

Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.

Evolving testingTreatment strategiesMetastatic colorectal cancerClinical trial data withColorectal cancerHer2 positiveHer2 crcHer2 antibodiesTrastuzumab deruxtecanT dxdDestiny crc01Dose adjustmentDose reductionInterstitial lung diseaseAsco 2023Asco annual meeting

HER2-Amplified Colorectal Cancer: Clinical Trial Data

A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.

Positive colorectal cancerNovel approachesAmplified colorectal cancerClinical trial dataColorectal cancerMetastatic crcColon cancerRectal cancerHer2 positiveTrastuzumab deruxtecanT dxdMountaineer trialMypathway trialDestiny crc01Destiny crc02Interstitial lung disease

vimarsana © 2020. All Rights Reserved.